AstraZeneca: CHMP Recommends Approval Of Tezspire In The EU
(RTTNews) - AstraZeneca and Amgen's Tezspire or tezepelumab has been recommended for approval in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps. The CHMP of the European Medicines Agency based its positive opinion on results from the WAYPOINT Phase III trial.
Regulatory applications are currently under review in the US, China, Japan and several other countries based on the WAYPOINT trial. Tezspire is approved for the treatment of severe asthma in the US, EU, Japan and more than 60 countries.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.